3项指标联合检测对卵巢癌诊断及分期的临床研究

目的探讨血清人附睾蛋白4(HE4)、糖类抗原125(CA125)以及癌胚抗原(CEA)3项肿瘤标志物联合检测在卵巢癌诊断及分期判断中的临床价值。方法选取该院2014年3月至2016年3月确诊的卵巢癌患者90例(卵巢癌组),良性卵巢疾病患者120例(良性组),以及60例健康女性(健康对照组),采用免疫化学发光法,检测3组人群的HE4、CA125和CEA水平,并进行比较分析。结果卵巢癌组3项指标显著高于良性组和健康对照组,差异具有统计学意义(P0.05),HE4、CA125、CEA联合检测卵巢癌Ⅰ~Ⅳ期的阳性率分别为81.2%、92.1%、97.4%和100.0%,且HE4、CA125、CEA联合检测在卵巢癌不同分期的阳性率要显著高于单一指标检测阳性率。结论采用HE4、CA125、CEA联合检测,对于卵巢癌诊断及分期判断的临床价值显著,值得进一步推广。

The value of combined detection of 3 indicators in diagnosis and staging of ovarian cancer

Objective To investigate the clinical value of combined detection of serum human epididymis protein 4(HE4),carbo-hydrate antigen 125(CA125)and tumor marker(CEA)in the diagnosis and staging of ovarian cancer.Methods 90 cases of ovarian cancer(ovarian cancer group),120 cases of benign ovarian disease(ovarian benign group)and 60 cases of healthy women(healthy control group)were selected from March 2014 to 2016 March in our hospital.The levels of HE4 and CA125 and CEA were detected by immunochemiluminescence assays,the results of the three groups were compared and analyzed.Results The positive rate of 3 indicators in the ovarian cancer group was significantly higher than that of the ovarian benign group and the healthy control group (P <0.05).The positive rates of combined detection of Ⅰ-Ⅳ in ovarian cancer were 81.2%,92.1%,97.4% and 100.0%,and CEA,CA125 and HE4 joint inspection in different stages of ovarian cancer positive rate is significantly higher than that of single in-dex positive detection rate.Conclusion The clinical value of HE4,CA125,CEA combined test for the diagnosis and staging of ovar-ian cancer is significant,it is worth to be further promoted.